<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711148</url>
  </required_header>
  <id_info>
    <org_study_id>ICP-CL-00112</org_study_id>
    <nct_id>NCT04711148</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing InnoCare Pharma Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing InnoCare Pharma Tech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-Blind, placebo-controlled Phase 2 Study of Orelabrutinib in&#xD;
      Patients with Relapsing-Remitting Multiple Sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study contains 2 parts: Core Part and an Open-label Extension (OLE) Part.&#xD;
&#xD;
      The Core Part is a randomized, double-blind, placebo-controlled, phase 2 study. Patients with&#xD;
      RRMS will be randomly assigned to 1 of 4 treatment groups. placebo, orelabrutinib (low dose),&#xD;
      orelabrutinib (medium dose) and orelabrutinib (high dose) at a 1:1:1:1 ratio.&#xD;
&#xD;
      The OLE part is an open-label, single treatment arm study to enroll patients who have&#xD;
      completed the Week 24 visit in the Core Part for continued treatment and collect additional&#xD;
      long-term safety and efficacy data.All patients will receive the low dose of orelabrutinib or&#xD;
      any other dose as suggested from the Core part of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The cumulative number of new GdE T1 MRI brain lesions</measure>
    <time_frame>up to 120 weeks</time_frame>
    <description>To evaluate the efficacy of orelabrutinib on the cumulative number of new gadolinium-enhancing (GdE) T1 magnetic resonance (MRI) brain lesions versus placebo over 12 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability ]</measure>
    <time_frame>up to 120 weeks</time_frame>
    <description>To evaluate the safety and tolerability of orelabrutinib compared to placebo in the Core Part</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARR[efficacy]</measure>
    <time_frame>up to 120 weeks</time_frame>
    <description>Annualized relapse rate in the OLE Part</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peak concentration (Cmax)</measure>
    <time_frame>up to 120 weeks</time_frame>
    <description>Dose Escalation Peak concentration (Cmax)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The Core Part：Participants receive placebo&#xD;
The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>orelabrutinib(low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Core Part：Participants receive low dose orelabrutinib&#xD;
The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>orelabrutinib(medium dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Core Part ：Participants receive medium dose orelabrutinib&#xD;
The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>orelabrutinib (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Core Part：Participants receive high dose orelabrutinib&#xD;
The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>orelabrutinib</intervention_name>
    <description>Orelabrutinib is a white, round, uncoated tablet</description>
    <arm_group_label>orelabrutinib (high dose)</arm_group_label>
    <arm_group_label>orelabrutinib(low dose)</arm_group_label>
    <arm_group_label>orelabrutinib(medium dose)</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Are 18 to 55 years of age at the time of signing the informed consent.&#xD;
&#xD;
          2. Are diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS).&#xD;
&#xD;
          3. Are neurologically stable for ≥ 30 days prior to both Screening and Baseline.&#xD;
&#xD;
          4. One or more documented relapses within the 2 years before Screening&#xD;
&#xD;
          5. Have an EDSS score of 0 to 5.5 at Screening and Baseline (Day 1)&#xD;
&#xD;
          6. Women of childbearing potential must use effective method of contraception&#xD;
&#xD;
          7. Signed and dated informed consent&#xD;
&#xD;
          8. Patient currently participating in the Core Part who has completed the end of&#xD;
             treatment visit and will be benefit from continued treatment per investigator's&#xD;
             assessment. (OLE Part only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with progressive MS.&#xD;
&#xD;
          2. Disease duration &gt; 10 years in participants with an EDSS ≤ 2.0 at Screening and&#xD;
             Baseline (Day 1).&#xD;
&#xD;
          3. Immunologic disorder other than MS.&#xD;
&#xD;
          4. History or current diagnosis of other neurological disorders that may mimic MS.&#xD;
&#xD;
          5. History or current diagnosis of progressive multifocal leukoencephalopathy (PML).&#xD;
&#xD;
          6. History of myocardial infarction or cerebrovascular event within 6 months prior to&#xD;
             Screening,&#xD;
&#xD;
          7. A history of attempted suicide within 6 months prior to Screening or a positive&#xD;
             response to items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at&#xD;
             Screening.&#xD;
&#xD;
          8. An episode of major depression within the last 6 months prior to Screening (clinically&#xD;
             stable minor depression is not exclusionary).&#xD;
&#xD;
          9. History of cancer, except adequately treated basal cell or squamous cell carcinoma of&#xD;
             the skin&#xD;
&#xD;
         10. Breastfeeding/lactating or pregnant women&#xD;
&#xD;
         11. Participants are excluded from participation in the study if taken prohibited&#xD;
             medications/treatments.&#xD;
&#xD;
         12. Participation in any investigational drug study within 6 months or 5 half-lives of the&#xD;
             investigational drug, whichever is longest, prior to Screening.&#xD;
&#xD;
         13. Permanent discontinuation from the Core Part due to AE/ SAE or abnormal abnormalities&#xD;
             or conditions leading to permanent study drug discontinuation. (OLE Part only)&#xD;
&#xD;
         14. Patient who has new abnormality appeared in the Core Part. (OLE Part only)&#xD;
&#xD;
         15. Any significant change in the subject's medical history that would preclude&#xD;
             administration of the study drug. (OLE Part only)&#xD;
&#xD;
         16. Clinically significant laboratory abnormalities from the most recently available test&#xD;
             in the Core Part that would preclude administration of the study drug. (OLE Part only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivia Yang</last_name>
    <phone>+1 (609) 524-0684</phone>
    <email>ClinicalTrialsInfo@innocarepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurology Associates of Ormond Beach</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalia Fulop</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Moreo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, P.C.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Pattee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premier Neurology, P.C.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Hughes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Xu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hangyu Zhou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NZOZ Wielospecjalistyczna Poradnia Lekarska &quot;Synapsis&quot;</name>
      <address>
        <city>Katowice</city>
        <zip>40-123</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Smilowski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prywatna Praktyka Lekarska</name>
      <address>
        <city>Katowice</city>
        <zip>40-571</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maciej Maciejowski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Resmedica NZOZ Kielce</name>
      <address>
        <city>Kielce</city>
        <zip>25-726</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elzbieta Jasinska, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nzoz &quot;Neuro-Kard&quot;</name>
      <address>
        <city>Poznan</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Ilkowski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CE I.I.Mechnykov Dnipropetrovsk RC Hosp of Dnipropetrovsk RC Dept of Neurology</name>
      <address>
        <city>Dnipro</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleksandr Kalbus, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center of Dnipro State Medical University, Dnipro State Medical University</name>
      <address>
        <city>Dnipro</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liudmyla Dziak, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SI USSRI of Medical and Social Problems of Disabilities of MOHU</name>
      <address>
        <city>Dnipro</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olena Moroz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNE Regional Clinical Hospital of Ivano-Frankivsk Regional Council</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galyna Chmyr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Neurology, Psychiatry and Narcology of NAMSU</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yevgeniya Lekomtseva, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SI Institute of Neurology, Psychiatry and Narcology of NAMSU</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataliya Voloshyna, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center of Limited Liability Company Medbud-Clinic</name>
      <address>
        <city>Kyiv</city>
        <zip>3110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larysa Sokolova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNE of Lviv Reg Council Lviv Reg Clin Hospital Dept of Neurology D.Halytskyi Lviv NMU</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tetyana Nehrych, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNE City Clinical Hospital #5 of Lviv</name>
      <address>
        <city>Lviv</city>
        <zip>79013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Khavunka, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNE Odesa Regional Clinical Hospital of Odesa Regional Council</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alla Goloborodko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center of Limited Liability Company Medical Center Saliutem</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergii Moskovko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise &quot;City Hospital No.6&quot; of Zaporizhzya City Council</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olexandr Kozyolkin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNE Zaporizhzhia Regional Clinical Hospital of ZRC</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alla Cherkez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center of Limited Liability Company INET-09</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataliya Tomakh, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Poland</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

